STERIS Beats Q3 Estimates with $1.59B Revenue, Lifts Full-Year EPS Guidance to $11.45   

Growth was driven by higher procedure volumes, increased sales of consumables and strong service performance. The company also received $20 million in tariff refunds, which helped improve its margins. Its operating margin stood at 18.5%.

STERIS raised its full-year adjusted earnings per share forecast to $11.45 at the midpoint, an increase of 2.2%.

CEO Dan Carestio said the acquisition of Xodus Medical has added a new clinical sales team focused on operating rooms. He also said the decline in inventory levels in its sterilisation services business has ended.

Read More:Numica Raises $21M in Combined Equity and Debt Financing

STERIS reported strong third-quarter results, supported by demand in its Healthcare and Life Sciences businesses. Revenue growth was driven by higher procedure volumes, increased sales of consumables and better service performance. CEO Dan Carestio said the company's product range and sales teams helped it perform well despite challenging market conditions.

The company's margins also benefited from $20 million in tariff refunds. However, inflation and higher research and development spending partly offset these gains.

STERIS reported third-quarter 2026 revenue of $1.59 billion, up 8.8% year over year and above analyst estimates of $1.56 billion. Adjusted earnings per share were $2.94, beating the expected $2.68 by 9.8%. Revenue at constant currency also increased 8.1%, while the operating margin remained steady at 18.5% compared to the same quarter last year.

The company raised its full-year adjusted earnings per share guidance to $11.45 at the midpoint, an increase of 2.2%. STERIS had a market capitalisation of $24.78 billion.

Read More:Kalepa Raises $75M in Series B Funding Led by Updata Partners